Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Tokyo  >  DAIICHI SANKYO COMPANY, LIMITED    4568   JP3475350009

SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

DAIICHI S : Notice on Details of the Share Options

share with twitter share with LinkedIn share with facebook
share via e-mail
0
07/12/2011 | 10:20am CEST
For Immediate Release

Company name: DAIICHI SANKYO COMPANY, LIMITED Representative: Joji Nakayama, President and CEO

(Code no.: 4568, First Section of Tokyo, Osaka and Nagoya Stock Exchanges) Please address inquiries to Toshiaki Sai, Corporate Officer, Vice President, Corporate Communications Department

Telephone: +81-3-6225-1126

http://www.daiichisankyo.com/Notice on Details of the Share OptionsTOKYO, Japan (July 12, 2011) Daiichi Sankyo Company, Limited has announced that the subscription amount and other details of its No.5 share options were decided today. As previously announced, the Board of Directors had reached a decision on June 27, 2011 to issue the said share remuneration-type stock options (share options) to remunerate Directors (excluding Outside Directors) and Corporate Officers

1. Name of share options

Daiichi Sankyo Company, Limited No. 5 share options

2. Total number of share options

2,328 share options (100 shares per one share option) Breakdown

Six (6) Directors: 1,102 share options

Eighteen (18) Corporate Officers: 1,226 share options

3. Subscription amount for share options

111,200 yen per share option

(1,112 yen per share)

Reference

Date of Board of Directors resolution: June 27, 2011

###
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on DAIICHI SANKYO COMPANY, LI
03/23 DAIICHI SANKYO : to Facilitate New Drug Discovery in 2017 through Collaborative ..
03/21 DAIICHI SANKYO : Daichii questions Singh brothers’ asset declaration
03/20 DAIICHI SANKYO : Ranbaxy’s former promoters refuse to pay Rs 2562 crore to..
03/20 DAIICHI'S RANBAXY PROFITS OUTWEIGH L : Singh brothers
03/17 DAIICHI SANKYO : The National Institutes of Biomedical Innovation, Health and Nu..
03/16 DAIICHI SANKYO : Initiates ENTRUST-AF PCI Study Investigating Once-Daily SAVAYSA..
03/16 DAIICHI SANKYO : Amring Pharmaceuticals Acquired Six ANDAs
03/15 DAIICHI SANKYO : Announces Large-scale Registry of Venous Thromboembolism (VTE) ..
03/15 Heptares adds Daiichi pain pact to string of R&D deals
03/14 DAIICHI SANKYO : Heptares Therapeutics enters agreement with Daichi Sankyo
More news
Sector news : Pharmaceuticals - NEC
03/24 NOVO NORDISK A/S : EMA panel backs Novo Nordisk's haemophilia B drug
03/24 YouTube's bid to grab TV dollars imperiled by advertiser revolt
03/23DJPRESS RELEASE : FDA Grants Approval for -3-
03/23DJPRESS RELEASE : FDA Grants Approval for -2-
03/23DJPRESS RELEASE : FDA Grants Approval for BAVENCIO(R) (avelumab), the First Immuno..
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
02/17 ArQule's lead product candidate tivantinib flunks late-stage liver cancer stu..
02/03 FDA rejects Charleston and Daiichi's opioid candidate
01/24 Pancreatic Cancer Field Awaits Sparse Data
01/18 Daiichi launches Japan-based study of breast cancer candidate U3-1402
01/10 RHEUMATOID ARTHRITIS : The Big 3 And The Future
Advertisement
Financials ( JPY)
Sales 2017 943 285 M
EBIT 2017 -
Net income 2017 73 154 M
Finance 2017 299 367 M
Yield 2017 2,71%
P/E ratio 2017 23,60
P/E ratio 2018 26,01
EV / Sales 2017 1,62x
EV / Sales 2018 1,69x
Capitalization 1 831 022 M
More Financials
Chart DAIICHI SANKYO COMPANY, LI
Duration : Period :
DAIICHI SANKYO COMPANY, LI Technical Analysis Chart | 4568 | JP3475350009 | 4-Traders
Full-screen chart
Technical analysis trends DAIICHI SANKYO CO...
Short TermMid-TermLong Term
TrendsBearishBullishNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 12
Average target price 2 412  JPY
Spread / Average Target -6,6%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Joji Nakayama President, CEO & Representative Director
Kentaro Takamura IR Contact, Manager-Finance & Accounting
Glenn J. Gormley Senior Managing Executive Officer, Head-R&D
Masahiko Ohtsuki Executive Officer & Senior Manager-Research
Kazunori Hirokawa Representative Director, VP & GM-Administration
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
DAIICHI SANKYO COMPANY..7.94%16 441
JOHNSON & JOHNSON8.91%340 163
ROCHE HOLDING LTD.8.73%219 545
PFIZER INC.4.68%202 474
NOVARTIS AG-0.94%195 096
MERCK & CO., INC.7.32%173 465
More Results